30% rise due in primary sclerosing cholangitis prevalence by 2040
The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Imdusiran combos lead to functional cure in some cases of hepatitis B
The investigational treatment imdusiran used as part of combination therapy regimens has led to a functional cure for eight people with chronic hepatitis…
AHB-137 effective for chronic hepatitis B: Phase 2b clinical trial
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
New Phase 2 trial data show benefits of elafibranor for PSC
Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…
MET gene mutations could be rare cause of MASLD, MASH
Rare mutations in the MET gene can cause metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, a study found. After…
Surgery eases symptoms of rare skull condition in boy with Alagille
Craniosynostosis — a condition usually identified in infancy where the bones in a baby’s skull join together prematurely — led to elevated pressure in the…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
GLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…
